-
1
المؤلفون: Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
المساهمون: University of Zurich, Dummer, Reinhard
المصدر: The Lancet Oncology. 19:1315-1327
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business
وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2 -
2
المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty
المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline
المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test -
3
المؤلفون: John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
المساهمون: University of Zurich, Long, Georgina V
المصدر: Journal of Clinical Oncology
J Clin Oncolمصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test -
4
المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto
المساهمون: University of Zurich, Hamid, Omid
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business
وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test -
5
المؤلفون: Kerstin Trunzer, Antoni Ribas, C. Lebbé, Dirk Schadendorf, Paul B. Chapman, Jeffrey A. Sosman, Axel Hauschild, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, Grant A. McArthur, Michele Maio, John M. Kirkwood, Thomas Jouary, Brigitte Dréno, Alexander M.M. Eggermont, John B. A. G. Haanen, James Larkin, Claus Garbe, Reinhard Dummer, Ivor Caro, Ming Yin, Paul Lorigan, Stephen J O'Day, Suzanne Cheng, David Hogg, Keith T. Flaherty, Caroline Robert
المساهمون: University of Zurich, McArthur, Grant A
المصدر: The Lancet. Oncology, vol 15, iss 3
مصطلحات موضوعية: Male, Indoles, Medizin, Gastroenterology, chemistry.chemical_compound, Vemurafenib, Melanoma, Cancer, Sulfonamides, education.field_of_study, Hazard ratio, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Dacarbazine, Oncology, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Population, 610 Medicine & health, Disease-Free Survival, Clinical Research, Internal medicine, Genetics, medicine, Humans, Oncology & Carcinogenesis, education, Protein Kinase Inhibitors, Aged, Cobimetinib, Performance status, business.industry, Prevention, medicine.disease, Surgery, Good Health and Well Being, chemistry, Mutation, business, Follow-Up Studies
وصف الملف: 573_McArthur_GA_et_al._-_Lancet_Oncol_2014.pdf - application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4Test
http://hdl.handle.net/11365/1081256Test -
6
المؤلفون: Marta Nyakas, Stuart Spencer, Mireille Cantarini, Reinhard Dummer, Gabriella Liszkay, Paul Lorigan, Ana Arance, Caroline Robert, Mark R. Middleton, Dirk Schadendorf, Ralf Gutzmer, Kevin B. Kim
المساهمون: University of Zurich, Robert, Caroline
مصطلحات موضوعية: Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, DNA Mutational Analysis, Medizin, Phases of clinical research, Kaplan-Meier Estimate, Gastroenterology, Antineoplastic Combined Chemotherapy Protocols, Melanoma, 10177 Dermatology Clinic, Middle Aged, Dacarbazine, Europe, Phenotype, Treatment Outcome, Oncology, Tolerability, Female, 2730 Oncology, Brazil, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Neutropenia, Placebo, Disease-Free Survival, Drug Administration Schedule, Double-Blind Method, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Antineoplastic Agents, Alkylating, Protein Kinase Inhibitors, Aged, Proportional Hazards Models, Chemotherapy, Intention-to-treat analysis, business.industry, medicine.disease, United States, Surgery, Logistic Models, Mutation, Selumetinib, Neoplasms, Unknown Primary, Benzimidazoles, business
وصف الملف: 555_Robert_C_et_al._-_Lancet_Oncol_2013.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c63162f2b90b77be9846693c33b4197Test
https://www.ncbi.nlm.nih.gov/pubmed/23735514Test -
7
المؤلفون: Levi A. Garraway, Antje Sucker, Emanuele Palescandolo, Piotr Dziunycz, Damien Kee, Nyam Kamsu-Kom, Patrick A. Oberholzer, Günther F.L. Hofbauer, Grant A. McArthur, Clinton J. Chalk, Caroline Robert, Adriano Piris, Robert T. Jones, Kristin G. Ardlie, Dirk Schadendorf, Christine Roden, Laura E. MacConaill
المساهمون: University of Zurich, Garraway, L A
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(3)
مصطلحات موضوعية: Sorafenib, Adult, Male, Niacinamide, Proto-Oncogene Proteins B-raf, Cancer Research, Indoles, Skin Neoplasms, Genotype, Pyridines, Medizin, 610 Medicine & health, medicine.disease_cause, Mass Spectrometry, CDKN2A, Original Reports, Carcinoma, medicine, Humans, 1306 Cancer Research, HRAS, Vemurafenib, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Mitogen-Activated Protein Kinase Kinases, Mutation, Sulfonamides, business.industry, Phenylurea Compounds, Benzenesulfonates, 10177 Dermatology Clinic, Middle Aged, medicine.disease, Gene Expression Regulation, Neoplastic, Oncology, Cancer research, Carcinoma, Squamous Cell, 2730 Oncology, Female, KRAS, business, medicine.drug
وصف الملف: RAS_Mutations_Are_Associated_With_the_Development_of_Cutaneous_Squamous_Cell_Tumors_in_Patients_Treated_With_RAF_Inhibitors_JCO_2011.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3567cff10b5be5b331260c345ce8a46Test
https://pubmed.ncbi.nlm.nih.gov/22067405Test